Every second German believes that the public-sector health funds could exercise better control over spending, says a study conducted for the Federation of Interior Health Funds by the Berlin opinion research company Forsa.
A third of those surveyed said doctors and politicians should fight harder to prevent the waste of health service money, while 85% said the funds should have additional means to control price-increasing practices by drug companies and medical equipment manufacturers.
The fund wanted to know if it was justified in setting up a working group to investigate the economics of medical products. The group is to cost 1.5 million Deutschemarks ($947,250) a year, including payment to an industry leader to investigate the issue of alleged payments of bribes to doctors. The fund believes over 1 billion marks more than is necessary is paid annually for medical products, including drugs, and calls for funds to be given the right to control prices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze